Growth Hormone for Osteoporosis Pseudoglioma Syndrome
Status: | Withdrawn |
---|---|
Conditions: | Osteoporosis, Ocular, Orthopedic |
Therapuetic Areas: | Ophthalmology, Rheumatology, Orthopedics / Podiatry |
Healthy: | No |
Age Range: | 4 - Any |
Updated: | 4/22/2017 |
Start Date: | December 2013 |
End Date: | December 2015 |
Trial of Growth Hormone for Osteoporosis Pseudoglioma Syndrome
Osteoporosis pseudoglioma (OPPG) syndrome is a rare autosomal recessive condition of
childhood osteoporosis and congenital blindness for which new treatments are needed. We have
found that body fat is increased in OPPG and muscle mass is reduced. We hypothesize that
growth hormone therapy will improve muscle mass and bone strength in OPPG.
childhood osteoporosis and congenital blindness for which new treatments are needed. We have
found that body fat is increased in OPPG and muscle mass is reduced. We hypothesize that
growth hormone therapy will improve muscle mass and bone strength in OPPG.
Osteoporosis pseudoglioma (OPPG) syndrome is a rare autosomal recessive condition of
childhood osteoporosis and congenital blindness for which new treatments are needed. We have
found that body fat is increased in OPPG and muscle mass is reduced. We hypothesize that
growth hormone therapy will improve muscle mass and bone strength in OPPG.
childhood osteoporosis and congenital blindness for which new treatments are needed. We have
found that body fat is increased in OPPG and muscle mass is reduced. We hypothesize that
growth hormone therapy will improve muscle mass and bone strength in OPPG.
Inclusion Criteria:
- Osteoporosis pseudoglioma syndrome
- Age 4 years and above
- not on medication for osteoporosis
Exclusion Criteria:
- pregnant
- Age under 4 yrs
- Active malignancy
We found this trial at
1
site
655 West Baltimore Street
Baltimore, Maryland 21201
Baltimore, Maryland 21201
(410) 706-7410
University of Maryland School of Medicine Established in 1807, The School of Medicine is the...
Click here to add this to my saved trials